ITI-007 (Lumateperone Tosylate) for Schizophrenia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Lumateperone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 23 Jan 2019 Status changed from planning to not yet recruiting.
- 04 May 2017 New trial record
- 01 May 2017 According to an Intra-Cellular Therapies media release, based on the responses regarding the nonclinical findings, US FDA may place hold on this trial. This trial will support an NDA approval for schizophrenia.